Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

A Mobile App to Reduce and/or Quit Cannabis Use

NCT06733792 · tracked via the Priya Life Science Spain tracker
Sponsor
Alba González-Roz, PhD
Phase
Not applicable
Started
2024-12-13
Last updated
2025-03-30

Condition(s) studied

Cannabis Dependence

Investigational drug(s) / intervention(s)

CBT-based interventionSelf-help guide

CBT-based intervention: * 1st week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health consequences, motives for cannabis use reduction/quitting, psychoeducation concerning withdrawal symptomatology, therapist's recommendation (progressive reduction of cannabis use). * 2nd week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health and behavioral consequences, identification of triggers, alternatives to cannabis use, therapist's recommendation (progressive reduction of cannabis use). * 3rd week: Daily self-report on cannabis and tobacco use benefits from quitting cannabis, behavioral activation, diaphragmatic breathing, training in social abilities, strategies to prevent smoking, therapist's recommendation (progressive reduction of cannabis use). * 4th week: Daily self-report on cannabis and tobacco use (i.e., nº of joints/cigarettes), high-risk situations for relapse, lapse vs. relapse, coping strategies, relapse prevention plan.

Self-help guide: Psychoeducation on cannabis.

Study summary

This study aims to develop an App-based intervention (CANQUIT) aimed at regular cannabis users. The efficacy of this intervention will be evaluated in the short-term (1-month follow-up) and long-term (3- and 6-months follow-ups) using a sample of 120 participants. Participants will be randomly assigned to the experimental arm (App-assisted CBT-based intervention) or the control (App-assisted self-help guide). The study will also estimate the economic impact of the intervention by considering the benefit-cost ratio (BCR) and net benefit (in €) associated with the total cost of the program. The goal is to provide evidence that can inform policy decisions regarding cannabis use and minimize the negative consequences on the physical and mental health of young adults in Spain. This study aims to offer a cost-effective prevention strategy that minimize the negative consequences on the physical and mental health of young adults in Spain.

Eligibility

Sex
ALL
Min age
18 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria: * Between 18 and 30 years old. * At least one occasion of cannabis use in the last month. * Access to smartphones (iOS or Android). * Access to Internet. Exclusion Criteria: \-

Primary outcome measure(s)

  • Cannabis abstinence — 7-day point prevalence abstinence (PP) at 4-week follow-up (FU), 3-months follow-up (FU), 6-months follow-up (FU)
    * Self-reported point prevalence cannabis abstinence * Continuous self-reported cannabis abstinence
  • Cannabis reduction — 4 weeks follow-up (FU), 3 months follow-up (FU), 6 months follow-up (FU)
    * Self-reported reduction in quantity of cannabis used on a weekly basis (daily joints, number of hashish/marijuana joints, grams) * Decreases in self-reported past-month frequency of cannabis use (i.e., once, less than one per week, once/twice per week, 3-4 times a week, 5-6 times a week, every day).
  • Acceptability — 4-week follow-up (FU)
    Client Satisfaction Questionnaire-8 (CSQ-8). The CSQ-8 is an 8-item questionnaire that evaluates the level of satisfaction with the treatment received by the participants. Scores range between 8-32, with higher scores indicating higher levels of satisfaction.

Trial sites (2)

FacilityCityRegionStatus
Faculty of Psychology, University of Oviedo Oviedo Principality of Asturias Recruiting
University of Oviedo Oviedo Principality of Asturias Active Not Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06733792 on ClinicalTrials.gov ↗ ← All trials in Spain